{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:54:24Z","timestamp":1767592464228,"version":"3.48.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systematic pelvic and aortic lymphadenectomy in stage IIB\u2013IVB patients with epithelial ovarian cancer, undergoing complete abdominal macroscopic resection with normal lymph nodes, was revealed to have no prognostic significance for survival in the LION trial. However, the proportion of patients with ovarian clear cell carcinoma (OCCC) in the LION trial was only 2.2%, so the significance of systematic retroperitoneal lymphadenectomy in patients with OCCC remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an ancillary analysis of 619 patients enrolled in a randomized phase III trial (JGOG 3017) in patients with OCCC. Of these, 89 were stage IIB to IVB, underwent a complete macroscopic resection, and had no grossly enlarged lymph nodes intraoperatively. Patients were divided into two groups: group A with lymphadenectomy and group B without lymphadenectomy. The Kaplan\u2013Meier method was used to calculate progression-free survival (PFS) and overall survival (OS) and the log-rank test and Cox proportional hazard model were used to compare the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 89 patients, 77 (86.5%) underwent a lymphadenectomy (group A), while 12 (13.5%) did not (group B). Three-year PFS were 62.3% in group A and 58.3% in group B (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.7705). Three-year OS were 73.0% in group A and 65.6% in group B (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.6346). No significant differences were observed between two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study did not demonstrate a definitive survival benefit from systematic lymphadenectomy in advanced OCCC patients with complete resection and clinically negative nodes. Given the small sample size, these results should be interpreted with caution and regarded as exploratory.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-025-02926-8","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T02:48:09Z","timestamp":1764211689000},"page":"184-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic impact of lymphadenectomy in patients with advanced ovarian clear cell carcinoma: an ancillary analysis of the JGOG3017-A4 study"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4466-2068","authenticated-orcid":false,"given":"Satoe","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1826-6723","authenticated-orcid":false,"given":"Muneaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1407-2393","authenticated-orcid":false,"given":"Yuri","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-5570","authenticated-orcid":false,"given":"Yuji","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2659-1449","authenticated-orcid":false,"given":"Takafumi","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-8641","authenticated-orcid":false,"given":"Koji","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8214-2242","authenticated-orcid":false,"given":"Tatsuyuki","family":"Chiyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9126-3361","authenticated-orcid":false,"given":"Yasuhisa","family":"Terao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2385-9040","authenticated-orcid":false,"given":"Toru","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5079-0464","authenticated-orcid":false,"given":"Aikou","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"2926_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010158","author":"M Roy","year":"2021","unstructured":"Roy M, Yang YP, Bosquet O et al (2021) Understanding the role and clinical applications of exosomes in gynecologic malignancies: a review of the current literature. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14010158","journal-title":"Cancers (Basel)"},{"issue":"10177","key":"2926_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/s0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I et al (2019) Epithelial ovarian cancer. Lancet 393(10177):1240\u20131253. https:\/\/doi.org\/10.1016\/s0140-6736(18)32552-2","journal-title":"Lancet"},{"issue":"24","key":"2926_CR3","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1200\/jco.2006.10.2517","volume":"25","author":"WE Winter 3rd","year":"2007","unstructured":"Winter WE 3rd, Maxwell GL, Tian C et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol 25(24):3621\u20133627. https:\/\/doi.org\/10.1200\/jco.2006.10.2517","journal-title":"J Clin Oncol"},{"key":"2926_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","volume":"80","author":"J Prat","year":"2018","unstructured":"Prat J, D\u2019Angelo E, Espinosa I (2018) Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol 80:11\u201327. https:\/\/doi.org\/10.1016\/j.humpath.2018.06.018","journal-title":"Hum Pathol"},{"issue":"27","key":"2926_CR5","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1200\/jco.19.00337","volume":"37","author":"C Gourley","year":"2019","unstructured":"Gourley C, Bookman MA (2019) Evolving concepts in the management of newly diagnosed epithelial ovarian cancer. J Clin Oncol 37(27):2386\u20132397. https:\/\/doi.org\/10.1200\/jco.19.00337","journal-title":"J Clin Oncol"},{"issue":"1","key":"2926_CR6","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2016.27.e5","volume":"27","author":"SI Kim","year":"2016","unstructured":"Kim SI, Lim MC, Lim J et al (2016) Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012. J Gynecol Oncol 27(1):e5. https:\/\/doi.org\/10.3802\/jgo.2016.27.e5","journal-title":"J Gynecol Oncol"},{"issue":"9 Suppl 3","key":"2926_CR7","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/igc.0000000000000289","volume":"24","author":"A Okamoto","year":"2014","unstructured":"Okamoto A, Glasspool RM, Mabuchi S et al (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer 24(9 Suppl 3):S20-25. https:\/\/doi.org\/10.1097\/igc.0000000000000289","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"2926_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1447-0756.2011.01755.x","volume":"38","author":"T Yahata","year":"2012","unstructured":"Yahata T, Banzai C, Tanaka K (2012) Histology-specific long-term trends in the incidence of ovarian cancer and borderline tumor in Japanese females: a population-based study from 1983 to 2007 in Niigata. J Obstet Gynaecol Res 38(4):645\u2013650. https:\/\/doi.org\/10.1111\/j.1447-0756.2011.01755.x","journal-title":"J Obstet Gynaecol Res"},{"issue":"6","key":"2926_CR9","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer 115(6):1234\u20131244. https:\/\/doi.org\/10.1002\/cncr.24149","journal-title":"Cancer"},{"issue":"9","key":"2926_CR10","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","volume":"380","author":"P Harter","year":"2019","unstructured":"Harter P, Sehouli J, Lorusso D et al (2019) A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 380(9):822\u2013832. https:\/\/doi.org\/10.1056\/NEJMoa1808424","journal-title":"N Engl J Med"},{"issue":"24","key":"2926_CR11","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1200\/jco.2016.66.9010","volume":"34","author":"T Sugiyama","year":"2016","unstructured":"Sugiyama T, Okamoto A, Enomoto T et al (2016) Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017\/GCIG trial. J Clin Oncol 34(24):2881\u20132887. https:\/\/doi.org\/10.1200\/jco.2016.66.9010","journal-title":"J Clin Oncol"},{"issue":"8","key":"2926_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/jjco\/hyad057","volume":"53","author":"S Fujiwara","year":"2023","unstructured":"Fujiwara S (2023) Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer. Jpn J Clin Oncol 53(8):664\u2013672. https:\/\/doi.org\/10.1093\/jjco\/hyad057","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"2926_CR13","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2021.32.e49","volume":"32","author":"H Tokunaga","year":"2021","unstructured":"Tokunaga H, Mikami M, Nagase S et al (2021) The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. J Gynecol Oncol 32(2):e49. https:\/\/doi.org\/10.3802\/jgo.2021.32.e49","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"2926_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/s0090-8258(02)00156-7","volume":"88","author":"CM Ho","year":"2003","unstructured":"Ho CM, Chien TY, Shih BY et al (2003) Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol 88(3):394\u2013399. https:\/\/doi.org\/10.1016\/s0090-8258(02)00156-7","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2926_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12885-021-08061-7","volume":"21","author":"C Zhu","year":"2021","unstructured":"Zhu C, Zhu J, Qian L et al (2021) Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study. BMC Cancer 21(1):322. https:\/\/doi.org\/10.1186\/s12885-021-08061-7","journal-title":"BMC Cancer"},{"issue":"3","key":"2926_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.107975","volume":"50","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhao W, Huang C et al (2024) The impact of lymphadenectomy on the survival outcomes of ovarian clear cell carcinoma: a retrospective study of the SEER database and Chinese registry. Eur J Surg Oncol 50(3):107975. https:\/\/doi.org\/10.1016\/j.ejso.2024.107975","journal-title":"Eur J Surg Oncol"},{"key":"2926_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.754149","volume":"11","author":"W Gao","year":"2021","unstructured":"Gao W, Shi P, Sun H et al (2021) Therapeutic role of retroperitoneal lymphadenectomy in 170 patients with ovarian clear cell cancer. Front Oncol 11:754149. https:\/\/doi.org\/10.3389\/fonc.2021.754149","journal-title":"Front Oncol"},{"issue":"7","key":"2926_CR18","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1245\/s10434-018-6412-y","volume":"25","author":"F Heitz","year":"2018","unstructured":"Heitz F, Harter P, Ataseven B et al (2018) Stage- and histologic subtype-dependent frequency of lymph node metastases in patients with epithelial ovarian cancer undergoing systematic pelvic and paraaortic lymphadenectomy. Ann Surg Oncol 25(7):2053\u20132059. https:\/\/doi.org\/10.1245\/s10434-018-6412-y","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2926_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/igc.0000000000000559","volume":"26","author":"JJ Mueller","year":"2016","unstructured":"Mueller JJ, Holzapfel M, Han CH et al (2016) Staging lymphadenectomy in patients with clear cell carcinoma of the ovary. Int J Gynecol Cancer 26(1):120\u2013124. https:\/\/doi.org\/10.1097\/igc.0000000000000559","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"2926_CR20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s00404-013-3078-3","volume":"289","author":"V Ulker","year":"2014","unstructured":"Ulker V, Kuru O, Numanoglu C et al (2014) Lymph node metastasis in patients with epithelial ovarian cancer macroscopically confined to the ovary: review of a single-institution experience. Arch Gynecol Obstet 289(5):1087\u20131092. https:\/\/doi.org\/10.1007\/s00404-013-3078-3","journal-title":"Arch Gynecol Obstet"},{"issue":"7","key":"2926_CR21","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1097\/IGC.0b013e3182856736","volume":"23","author":"H Mahdi","year":"2013","unstructured":"Mahdi H, Moslemi-Kebria M, Levinson KL et al (2013) Prevalence and prognostic impact of lymphadenectomy and lymph node metastasis in clinically early-stage ovarian clear cell carcinoma. Int J Gynecol Cancer 23(7):1226\u20131230. https:\/\/doi.org\/10.1097\/IGC.0b013e3182856736","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"2926_CR22","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e69","volume":"29","author":"K Matsuo","year":"2018","unstructured":"Matsuo K, Machida H, Mariani A et al (2018) Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer. J Gynecol Oncol 29(5):e69. https:\/\/doi.org\/10.3802\/jgo.2018.29.e69","journal-title":"J Gynecol Oncol"},{"issue":"7","key":"2926_CR23","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1136\/ijgc-2019-000287","volume":"29","author":"L Hogen","year":"2019","unstructured":"Hogen L, Vicus D, Ferguson SE et al (2019) Patterns of recurrence and impact on survival in patients with clear cell ovarian carcinoma. Int J Gynecol Cancer 29(7):1164\u20131169. https:\/\/doi.org\/10.1136\/ijgc-2019-000287","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02926-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02926-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02926-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:51:21Z","timestamp":1767592281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02926-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2926"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02926-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}